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Underrecognition and Undertreatment of
Atherothrombotic Diseases: REACH 
Registry Taiwan Baseline Data
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Mao-Lin Sung,6 Wen-Long Tsao,7 Ping-Keung Yip,8 Chiau-Suong Liau;9* 
on behalf of the Taiwan REACH Registry Investigators
Background/Purpose: Atherothrombosis is a generalized disease affecting different vascular beds, making it
the leading cause of death worldwide. To evaluate the long-term risk of atherothrombotic risk factors and
determine the predictors for atherothrombotic events, an international, prospective, observational study
was initiated, in which Taiwan was involved.
Methods: The REduction of Atherothrombosis for Continued Health (REACH) Registry recruited outpatients
with either symptomatic atherothrombotic diseases or multiple risk factors. Baseline data were collected using
a universal standard case report form. All subjects were followed to document future outcomes. In this paper,
we analyzed the baseline data of the participants from Taiwan.
Results: In the REACH Registry, a total of 67,888 subjects from 44 countries were recruited. Among the 1062
Taiwanese participants, 971 were symptomatic subjects and 91 subjects were with risk factors only (RFO). In
comparison with the global participants, the Taiwan patients were younger, with a higher prevalence of males,
lower prevalence of hypertension, obesity, hypercholesterolemia, former smokers, and a greater prevalence
of non-smokers. The baseline prevalence rates were: hypertension, 46.5%; fasting hyperglycemia, 38.4%;
hypercholesterolemia, 45.8%; and hypertriglyceridemia, 42.8%. All these prevalence were higher than the
global data, indicating an undertreatment status for the Taiwanese patients. Only 29 (2.7%) peripheral arterial
disease (PAD) subjects were recruited in Taiwan, suggesting underrecognition of this disease. The RFO
Taiwanese patients had fewer former smokers and more non-smokers than the symptomatic patients, suggest-
ing that smoking may be an important factor contributing to atherothrombotic diseases.
Conclusion: In Taiwan, atherothrombotic outpatients were generally undertreated and PAD was under-
diagnosed. [J Formos Med Assoc 2007;106(7):548–557]
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Atherosclerosis is a progressive disease affecting
the large and medium-sized arteries of the body.
At an advanced stage, the lumen of the involved
arteries may be severely narrowed, compromising
blood supply to the tissues. Or, the atheroscle-
rotic vessel may have thrombus formation on the
diseased atherosclerotic inner surface, resulting in
sudden severe reduction or even total cessation
of blood flow, the process of atherothrombosis.
“Atherothrombosis”, defined as disruption of an
atherosclerotic plaque with superimposed throm-
bosis1,2 was introduced to describe the common
underlying vascular occlusive mechanism in dif-
ferent vascular beds. Clinical atherothrombotic
diseases may include angina pectoris, and myo-
cardial infarction (MI) secondary to coronary artery
disease (CAD), transient ischemic attack (TIA)
and cerebral ischemic stroke (CI) resulting from
cerebrovascular disease (CVD), and critical limb
ischemia due to peripheral arterial disease (PAD).1
Atherothrombosis is the leading cause of death
worldwide, accounting for approximately one-
fourth of all-cause mortality in the world in the
year 2000,3,4 and thus becoming a major public
health issue in need of attention.
Many studies have demonstrated the benefits
of treating atherothrombotic risk factors for the
prevention of cardiovascular or cerebrovascular
events. However, randomized controlled trials do
not always provide an accurate view of current
clinical practice. In contrast, observational studies
enable a real-world estimation of actual disease
treatments. The Framingham Study,5 for exam-
ple, provides data on risk factors for developing
atherothrombosis. However, as most observational
studies are restricted to a particular geographic
locale, it is difficult to extrapolate data for a global
population.
The REduction of Atherothrombosis for Con-
tinued Health (REACH) Registry is an interna-
tional, observational registry initiated to determine
whether atherosclerosis risk factor prevalence and
treatment would demonstrate comparable pat-
terns in many countries around the world; and,
to evaluate the long-term risk of atherothrombosis.
The REACH Registry better defined the profile of
subjects at risk of atherothrombosis, the predic-
tors for atherothrombotic events, reinforced the
notion that atherothrombosis is a generalized
disease, and the importance of the cross risks for
atherothrombotic subjects.
The present study compares the baseline 
data from the Taiwan REACH Registry with the
baseline data from the global REACH Registry to
characterize Taiwanese patients who either have
atherothrombotic diseases or have only multiple
atherothrombosis risk factors.
Materials and Methods
The REACH Registry is an international, prospec-
tive, observational registry designed to provide 18–
24 months of follow-up. Patients were enrolled
from 44 countries in the following regions: North
America, Latin America, Western Europe, Eastern
Europe, Australia, Asia, and the Middle East.
The study recruited outpatients aged 45 years-
plus with either documented CAD, CVD and/or
PAD, or with at least three atherothrombotic risk
factors, over a 7-month period between December
2003 and June 2004. Documented CAD consisted
of one or more of the following criteria: stable
angina, a history of unstable angina, a history of
coronary angioplasty or stenting, a history of coro-
nary artery bypass graft, or previous MI. Documen-
ted CVD consisted of a hospital or neurologist
report with the diagnosis of TIA or previous CI.
Documented PAD consisted of one or both crite-
ria: current intermittent claudication with an ankle
brachial index (ABI) <0.9 or a history of intermit-
tent claudication together with a previous and
related intervention (angioplasty, bypass graft, or
other vascular intervention, including amputa-
tion). Subjects with more than one vascular bed
morbidity were eligible for enrolment. Patients
without documented atherothrombotic diseases
but with at least three of the following athero-
thrombotic risk factors might also be recruited:
type I or II diabetes currently treated with hypo-
glycemic agents, evidence of diabetic nephropa-
thy (microalbuminuria of ≤ 30 µg/mL), known
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ABI of < 0.9, carotid intima media thickness ex-
ceeding twice that of adjacent sites, known asymp-
tomatic carotid stenosis of ≥ 70%, systolic blood
pressure (SBP) of ≥150 mmHg, despite therapy for
at least 3 months, hypercholesterolemia currently
treated with medication, current smoking of at
least 15 cigarettes per day, men aged ≥65 years, or
women aged ≥70 years. The body mass index
(BMI) was defined as weight in kilograms divided
by the square of height in meters. Subjects with a
BMI of 25–29 were considered overweight and
subjects with a BMI of ≥ 30 were considered
obese. Obese subjects were further classified into
class I (BMI, 30 – < 35) and class II obesity (BMI,
≥ 35). Another measure of obesity was a waist cir-
cumference of ≥ 102 cm (40 inches) in men, or
≥88 cm (35 inches) in women. Current smoking
was defined as at least 5 cigarettes per day on aver-
age within the last month before entry into the
REACH Registry; and former smoking was defined
as at least 5 cigarettes per day on average for
more than 1 month before entry into the REACH
Registry; all others were defined as non-smokers.
Subjects already in a clinical trial, hospitalized
inpatients, or those who were expected to have
difficulty returning for a follow-up visit were 
excluded from enrolment.
Data were collected from eligible subjects at
recruitment using a universal standardized inter-
national case report form, including physician
profile, demographic information, employment
status, medical history, risk factors, physical exami-
nation, and current chronic medical treatment at
baseline.
Selection of physicians to the REACH Registry
was determined at the country level and included:
general practitioners or specialists, including cardi-
ologists, neurologists, internists, angiologists, dia-
betologists, and vascular surgeons. Each physician
recruited a maximum of 15 subjects (up to 20 sub-
jects in the United States). Such enrolment allowed
extrapolation of the recruitment results to the
broadest possible population at risk of athero-
thrombotic events. In order to ensure that the study
population was representative of the overall patient
pool, a site selection method was designed and
implemented in each participating country by
epidemiologists under supervision of the REACH
Registry global and local steering committees and
national coordinators. The site selection method
accounted for patient profiles, health care environ-
ments and medical practices. This was designed
to get a good reflection of the burden of athero-
thrombosis or at-risk populations.
This registry was conducted in accordance with
the principles set forth by the 18th World Medical
Assembly (Helsinki, 1964) and the protocol was
reviewed by the institutional review board as a
local request and signed informed consents were
obtained from all recruited patients.
Continuous variables are expressed as mean
(standard deviation [SD]). Categorical variables
are expressed as frequencies and percentages.
Comparisons between categorical variables were
performed using the Pearson χ2 test. The t test
was used to compare continuous variables.
Statistical significance level was set at less than
0.05 with a two-tailed probability. Age and gen-
der were adjusted using a logistic regression
model. Statistic analysis was performed using
SAS software version 8 (SAS Institute Inc., Cary,
NC, USA).
Results
A total of 69,055 subjects were enrolled in the
REACH Registry from 44 countries in different
regions. The distribution of subjects recruited
from different regions and the specialty of the 
recruiting physicians have been published else-
where.3 Of these recruited subjects, 1109 did not
meet the inclusion criteria, and 58 withdrew
their consent, leaving 67,888 subjects for data
collection and analysis. In Taiwan, 1062 subjects
were recruited by 74 physicians from 35 hospi-
tals, including general practitioners (3%), neu-
rologists (42%), cardiologists (36%), internists
(12%), endocrinologists (5%), general surgeons
(1%), and angiologists (3%). The baseline demo-
graphic data of the Taiwanese population and
the global subjects are listed in Table 1.
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The mean (SD) age of the Taiwanese subjects
was 66.3 (9.62) years, and 68.6% of the total pop-
ulation were male. In comparison with global data
in the REACH Registry, the Taiwanese population
was younger (66.3 years vs. 68.5 years) and pre-
dominantly male (68.6% vs. 63.7%), had a lower
prevalence of hypertension (75.3% vs. 81.8%),
obesity (22.7% vs. 46.6% by waist circumference),
and hypercholesterolemia (47.8% vs. 72.4%), had
a lower prevalence of former smokers (25.9% vs.
41.6%), and a higher prevalence of non-smokers
(56.2% vs. 43.1%), all reaching statistical signifi-
cance (p < 0.05).
There were 91 (8.57%) asymptomatic patients
with risk factors only (RFO). In comparison with
the symptomatic group in Taiwan, the RFO group
was older in age (69.2 years vs. 66.0 years), predom-
inantly female (44.0% vs. 30.3%), with a higher
prevalence of diabetes (82.4% vs. 40.4%), hyper-
tension (83.5 vs. 74.6%), and hypercholestero-
lemia (72.5% vs. 45.5%), but a lower prevalence
of former smokers (9.1% vs. 27.4%) and a higher
prevalence of non-smokers (69.3% vs. 55.0%),
all reaching statistical significance (p < 0.05).
Only 29 (2.7%) of the 971 symptomatic 
patients were diagnosed as having PAD. This per-
centage was much less than that of the global
population (2.7% vs. 14.9%, p < 0.05). In com-
parison with patients without PAD, PAD patients
were older (69.6 years vs. 65.9 years), had a higher
prevalence of diabetes (51.7% vs. 40.0%) and
hypercholesterolemia (58.6% vs. 45.1%), a lower
prevalence of obesity (13.8% vs. 22.5%), a lower
prevalence of former smokers (24.1% vs. 27.5%),
and a higher prevalence of non-smokers (65.5% vs.
54.7%) (data not shown).
Table 2 shows that, of the 1062 subjects, 90
(8.5%) had polyvascular disease. The proportion
of patients with polyvascular disease was relatively
lower in Taiwan than in the global population
(8.5% vs. 15.9% in the total population and
9.5% vs. 19.5% in the symptomatic subjects).
Documented high blood pressure (systolic
≥140 mmHg and/or diastolic ≥90 mmHg), fasting
hyperglycemia (glucose ≥ 126 mg/dL [6.99 mmol/
L]), hypercholesterolemia (≥ 200 mg/dL [5.18
mmol/L]), and hypertriglyceridemia (≥150mg/dL)
were recorded in a substantial number of patients
at baseline (Table 3). Hypertension was present
in 46.5% (range, 39.6–53.4%; and highest in the
CVD patients), fasting hyperglycemia in 38.5%
(range, 36.9–57.7%; and highest in the RFO sub-
jects), hypercholesterolemia in 45.8% (range,
44.9–59.3%; and highest in the PAD patients),
Table 2. Prevalence of polyvascular disease in the global and Taiwan REACH Registry populations
Population (%)*
Global total Taiwan total (n)
Single arterial bed
Overall 65.9 83.0 (881)
CAD alone 44.6 42.7 (454)†
CVD alone 16.6 39.4 (418)
PAD alone 4.7 0.9 (9)
Polyvascular disease
Overall 15.9 8.5 (90)
CAD + CVD 8.4 6.6 (70)
CAD + PAD 4.7 1.1 (12)
CVD + PAD 1.2 0.3 (3)
CAD + CVD + PAD 1.6 0.5 (5)
Multiple risk factors 18.3 8.6 (91)
*Unless otherwise indicated, p<0.05 for all comparisons; †p≥0.05 (not significant). CAD = coronary artery disease; CVD = cerebrovascular
disease; PAD = peripheral arterial disease; REACH = REduction of Atherothrombosis for Continued Health.
Underrecognition and undertreatment of atherothrombotic diseases
J Formos Med Assoc | 2007 • Vol 106 • No 7 553
and hypertriglyceridemia in 42.8% (range, 41.1–
63.0%; and highest in the PAD patients) of the
subjects.
Antihypertensive agents, hypoglycemic agents,
lipid-lowering agents, and antiplatelet/anticoag-
ulant medications were frequently used in these
patients (Table 4). In the Taiwan REACH Registry,
95.2% of hypertensive patients received at least one
antihypertensive agent—highest in CAD patients
(97.8%) and lowest in PAD patients (91.7%)—
which was lower than the 95.8% treatment rate in
the global population. However, the Taiwanese
population received antiplatelet agents more fre-
quently than the global population (84.7% vs.
78.6%)—highest in the CAD patients (90.8%)
and lowest in the PAD patients (69.0%). Diabetes
medication and lipid-lowering agents were used
less frequently in the Taiwanese population, at-
tributed to the low prevalence of diabetes and
hyperlipidemia.
Discussion
The REACH Registry is a global study which in-
cluded subjects of different ethnicities and differ-
ent populations at high risk for atherothrombotic
diseases. These patients are expected to have a
high probability of suffering disease recurrence
or new atherothrombotic events in the future.
The final results may demonstrate the long-term
risks of atherothrombosis in the high-risk popu-
lations and will define the profile of subjects at
risk for atherothrombosis and the predictors for
atherothrombotic events. By recruiting outpatients,
subjects were able to visit medical clinics and
tended to be stable, with mild morbidities, and
good compliance with medications. These charac-
teristics might lead to an underestimation of the
endpoint events and undertreatment of the pa-
tients. However, baseline data from the Taiwan
REACH Registry showed that there was a high pro-
portion of treated patients not achieving thera-
peutic target levels for hypertension, diabetes and
hyperlipidemia. The same observation applied to
the global REACH Registry.6
The CAD and CVD mortality rates in Taiwan
have decreased since 1994 (Figure).7 However,
CVD and CAD were still the second and third
leading causes of death in Taiwan in 2005, respec-
tively.7 The annual mortality rate for CVD was 57.8
per 105 (9.5% of all-cause mortality) and 57.1 per
105 (9.3% of all-cause mortality) for CAD. Up to
18.8% of the unadjusted mortalities were from
CVD and CAD,7 which is lower than the corre-
sponding worldwide data of 24% in 2000.3,4 More
aggressive therapeutic strategies to reach the treat-
ment targets for risk factor control are required.
The recognition of most atherothrombotic
risk factors was from studies conducted in North
America5 or Europe.8 However, considerable data
suggested that these risk factors varied in different
areas and populations.9 For example, hypercholes-
terolemia is not a CAD risk factor in Indians10 as it
is in people of European descent.9 The REACH
Registry also provided a chance to evaluate the 
importance of variable risk factors in different sub-
groups. The Taiwan REACH Registry population
Table 3. Undertreatment among patients in the global and Taiwan REACH Registry populations
Population (%)*
Symptomatic CAD CVD PAD ≥ 3 risk factors Taiwan total Global total
(n = 971) (n = 541) (n = 496) (n = 29) (n = 91) (n = 1062) (N = 67,888)
Measured hypertension‡ 46.32 39.63 53.36 48.28 48.89 46.54 49.97
Abnormal glycemia§ 36.61 37.02 36.89 48.15 57.65 38.45 30.66
Abnormal cholesterol|| 45.51 44.90 46.58 59.26 48.31 45.77 39.28
Abnormal triglycerides¶ 42.28 41.14 45.39 62.96 48.31 42.83† 44.21
*Unless otherwise indicated, p < 0.05 for all comparisons between global and Taiwan populations; †p ≥ 0.05 (not significant); ‡measured hypertension
≥140/90mmHg; §abnormal glycemia ≥126mg/dL; ||abnormal cholesterol ≥200mg/dL; ¶abnormal triglycerides ≥150mg/dL. CAD = coronary artery disease;
CVD = cerebrovascular disease; PAD = peripheral arterial disease; REACH = REduction of Atherothrombosis for Continued Health.
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had a high prevalence of hypertension and dia-
betes, similar to that of the global REACH Registry
population, but a significantly lower prevalence of
obesity (either by waist circumference or by BMI
criteria), hypercholesterolemia, and a higher pro-
portion of non-smokers. These results partially
explained the lower mortality rates for CAD and
CVD in Taiwan. In the Taiwan REACH Registry
population, there was also a significantly higher
prevalence of non-smokers in the RFO group than
in the symptomatic group, a significantly higher
prevalence of hypertension, diabetes, and hyper-
cholesterolemia, and a slightly higher prevalence
of obesity in the RFO group. Smoking was prob-
ably not only an independent risk factor for
atherothrombosis, but also has a synergistic effect
in causing atherothrombotic events.
Smoking is a general risk factor for athero-
thrombotic disease. Smoking accounted for a pop-
ulation attributable risk (PAR) of 35.7% with an
odds ratio (OR) of 2.87 for current and former ver-
sus non-smokers in the CAD population.11 This
effect was lower than increased apolipoprotein
(Apo) B/ApoA1 ratio (PAR, 49.2; OR, 3.25), and
higher than hypertension (PAR, 17.9; OR, 1.91),
diabetes (PAR, 9.9; OR, 2.37), and abdominal
obesity (PAR, 20.1; OR, 1.12) as seen in the global
REACH Registry baseline data.12 Active smokers
have up to an 80% increased risk of CAD and pas-
sive smokers have at least a 30% increased risk of
CAD.12 Smoking was also a risk factor for CVD
with an event attributable risk of 30% for current
smokers in Japan.13 The total excess relative risk
(RR) of stroke was 1.6 (95% confidence interval
[CI], 1.1–2.4), and up to 2.3 (95% CI, 1.2–4.4) in
hypertensive patients.13 Smoking could contribute
to 50% symptomatic PAD with a dose-dependent
increased prevalence of 2.3-fold in current smok-
ers and 2.6-fold in former smokers.14 Smokers of
all ages have a two-to-three times higher death rate
than non-smokers.4 CAD was the leading cause of
smoking-related premature death.15 It was esti-
mated that 1.69 million of the deaths were caused
by CAD, accounting for 11% of total global CAD
deaths.15 Smoking cessation will decrease the risk
of CAD with a hazard ratio (HR) of 0.71 (95% CI,
0.64–0.78) and ischemic stroke with a HR of
0.84 (95% CI, 0.76–0.92).16 In the Taiwan
REACH population, the prevalence of former and
current smokers was 44.8%, which was higher
than the 39.88% of Taiwan smoking prevalence
in men in 200517 and 20–30% smoking preva-
lence in Western countries.18 In order to decrease
atherothrombotic morbidity and mortality, smok-
ing abstinence and cessation should be strongly
encouraged.
The prevalence of obesity is increasing and has
become a global public health problem. Over-
weight and obesity increase CAD risk by 1.40- to
1.65-fold in men and 1.32- to 1.83-fold in women,
respectively.19 Obesity also increases CVD risk by
1.86-fold in men and 1.21-fold in women.20 Each
one-unit increase in BMI increases the multiple
adjusted risk of ischemic stroke and hemorrhagic
stroke by 4% and 6%, respectively.21 Epidemi-
ologic data suggest that the same BMI in different
ethnicities and races represent different risks. For
example, the Asian American population with BMI
<25 kg/m2 had a high percentage of metabolic risk
factors and abdominal obesity.22 A study found
that the relationship between percent body fat and
BMI differs between different ethnic groups. For
the same level of body fat, age and gender, the
BMIs of Chinese, Ethiopians, Indonesians and
Thais are 1.9, 4.6, 3.2 and 2.9 kg/m2 lower com-
pared to Caucasians.23 In the REACH Registry,
overweight, obesity, and abdominal obesity were
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1994–2005. [Source: Reference 7.]
T.J. Cheng, et al
556 J Formos Med Assoc | 2007 • Vol 106 • No 7
based on the WHO definition.24,25 Since this def-
inition makes no allowance for different ethnic
groups, baseline data from the Taiwan REACH
Registry reported a low prevalence of obesity.
Therefore, in order to accurately assess the obe-
sity risk in the Taiwan REACH Registry, it is nec-
essary to establish an obesity index appropriate
for the Taiwanese population based on regional
considerations.
Only 29 (2.7%) PAD subjects were identified
either with PAD alone or with polyvascular dis-
eases in the Taiwan REACH Registry, attributed to a
very low ABI examination rate. This prevalence was
lower than the 14.9% in the global REACH Registry
and that of the general population which was 
estimated at about 3.9% in males and 3.3% in fe-
males26 and was highly age-dependent, with a
range from 2.5% in people <60 years of age, 8.3%
in the 60–69 year age group, and up to 18.8% in
those ≥70 years of age.27 The prevalence increased
to 29% in primary care clinics and only 49% of
them were aware of PAD by physician.28 Comorbi-
dities of CAD or CVD are common in PAD pa-
tients. Based on the PARTNERS program, about
44% of PAD patients from primary care clinics had
PAD alone and 56% of PDA patients had PAD
combined with CAD.28 The prevalence of CVD
in PAD patients varied between 0.5% and 15%
by history and would be up to 90% by angiogra-
phy.29 The long-term risk for large vessel PAD 
patients is very high, with a RR of 3.1 in all-cause
mortality, 5.9 in cardiovascular deaths, and 6.6
in CAD deaths; the mortality rate would increase
15-fold if PAD was both severe and symptomatic
in 10 years of follow-up.30 However, PAD patients
frequently receive inadequate risk factor control
and antiplatelet treatment,28,30 and would have 
a poorer hospital outcome following an acute
coronary event.31 Low awareness and undertreat-
ment of PAD is likely to be a universal problem.
Therefore, the identification and treatment of PAD
as well as CAD and CVD could reduce athero-
thrombotic morbidity and mortality.
In conclusion, the baseline data from the
Taiwan REACH Registry show that outpatients
with documented atherothrombotic disease or
multiple risk factors were largely undertreated
for risk factor control, and PAD patients were un-
derdiagnosed. Therefore, strategies for risk factor
control, for example, smoking and obesity, should
be introduced in an effort to reduce athero-
thrombotic risk in the Taiwanese population.
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